Organ transplant shortages, the difficulty of traumatic repair, and irreversible tissue damage associated with chronic diseases remain core challenges in global healthcare. By precisely combining cells, biomaterials, and bioactive factors, 3D bioprinting enables the fabrication of tissue-engineered constructs with three-dimensional architecture and partial physiological function, providing new pathways for organ replacement, tissue repair, and personalized medicine. Systematic design centered on bioinks, printing processes, and tissue functional reconstruction is becoming a critical technological foundation for translating regenerative medicine from laboratory research to clinical practice.
I. Overview of Regenerative Medicine and 3D Bioprinting
1.1 Organ Shortage and the Need for Tissue Repair
The supply–demand imbalance in organ transplantation is severe, and the global organ supply has long remained far below clinical demand; large numbers of patients with end-stage organ failure cannot receive treatment due to the lack of suitable donors. Meanwhile, tissue defects and functional impairments caused by severe trauma, extensive tumor resection, and chronic diseases such as diabetes are also difficult to fully reverse through conventional surgery and pharmacotherapy. Regenerative medicine aims to reconstruct damaged tissue structure and function by mobilizing stem cells, scaffold materials, and bioactive factors; however, classical tissue engineering has clear limitations in fine spatial architecture, individualized fit, and the construction of complex tissues.
1.2 Basic Concept of 3D Bioprinting
Based on computer-aided design, 3D bioprinting deposits “bioinks” containing cells and/or biomaterials layer-by-layer along predefined paths to build three-dimensional living constructs with specific geometries, microstructures, and biological functions. Compared with the traditional approach of scaffold fabrication followed by cell seeding, 3D bioprinting offers clear advantages in spatial precision, multi-material integration, and personalized shape reproduction. It can more closely recapitulate native extracellular matrix architecture, compositional gradients, and mechanical microenvironments, thereby more effectively supporting cell survival, differentiation, and functional maturation.
II. Core Technical Elements of 3D Bioprinting
2.1 Bioinks
(1) Composition and Performance Requirements
Bioinks must strike a balance between “printability” and “favorable biological performance.” On the one hand, materials must exhibit appropriate rheological behavior during printing: viscosity decreases under shear within the nozzle to facilitate extrusion or jetting, and viscoelasticity rapidly recovers after deposition to maintain shape; additionally, before and after crosslinking/curing, the overall structure must provide sufficient mechanical support to prevent collapse. On the other hand, bioinks must demonstrate good cytocompatibility and low toxicity, allowing cells to adhere, migrate, proliferate, and secrete extracellular matrix in a three-dimensional environment; their degradation process and by-products must also match the time scale of tissue regeneration.
(2) Representative Material Systems
Common bioink materials can be broadly divided into natural polymers and synthetic polymers. Natural materials such as gelatin, sodium alginate, hyaluronic acid, and collagen feature favorable bioactivity and cell-adhesive properties, but their mechanical strength and batch-to-batch consistency are relatively limited; synthetic polymers such as polyethylene glycol derivatives and polylactic acid (and copolymers thereof) allow controllable mechanical properties, degradation rates, and chemical functionalities, yet often lack cell-recognition motifs and thus require peptide or growth-factor modification to enhance bioactivity. In practice, composite formulations combining natural and synthetic materials are frequently used and are customized according to tissue type and printing modality.
2.2 Printing Process Pathways
(1) Extrusion-Based Bioprinting
Extrusion-based bioprinting uses pneumatic pressure, a piston, or a screw to continuously extrude viscoelastic bioinks and stack them layer-by-layer. It features broad material compatibility, the ability to accommodate high cell densities, and facile integration of multiple printheads, making it suitable for constructing large-volume tissue constructs from the millimeter to centimeter scale. Key challenges include potential cell damage from shear stress within the nozzle and relatively limited structural resolution. Optimization of nozzle diameter, printing pressure, speed, and material rheology is required to balance shape fidelity and cell viability.
(2) Inkjet Bioprinting
Inkjet bioprinting deposits bioinks on demand as microdroplets, enabling a “dot-matrix” style, high-precision distribution of cells and materials. It offers fast printing, relatively high resolution, and comparatively low shear stress on cells. This approach is well suited to low-viscosity inks and relatively low-solid-content systems, and is often used to fabricate cell arrays, gradients, or thin tissue models. Due to the viscosity window and nozzle clogging risks, inkjet printing remains constrained in applications requiring high mechanical support and thick tissue construction.
(3) Photocuring-Based Bioprinting
Photocuring approaches (e.g., stereolithography or digital light processing) crosslink photosensitive hydrogels by spatially controlled light fields, enabling high-resolution fabrication of complex internal channels and continuous gradient structures. This modality is advantageous for organ-on-chip scaffolds, small-scale fine architectures, and complex microstructured tissue models, but requires precise control of light dosage and initiator systems to avoid cell damage from excessive irradiation and free radicals. Balancing construct thickness with light penetration depth is also a key process-design consideration.
2.3 Crosslinking and Structural Stability
(1) Physical and Ionic Crosslinking
Thermoresponsive gels, thermoreversible sol–gel systems, and ionic crosslinking systems are often used in bioprinting for “rapid shape fixation.” For example, gelatin gels upon cooling, and sodium alginate forms networks via calcium-ion crosslinking. These methods are mild and fast, making them suitable for coupling with extrusion printing to achieve preliminary structural stabilization during printing. However, physical or ionic crosslinking alone often cannot provide long-term mechanical strength and stability, and is therefore commonly combined with secondary crosslinking mechanisms.
(2) Chemical and Photocrosslinking
Chemical approaches such as photocrosslinking and enzymatic crosslinking can form stable covalent networks under relatively low temperatures and aqueous conditions, thereby substantially enhancing scaffold mechanical performance and shape retention. By controlling light intensity, exposure time, and photoinitiator concentration, rapid curing can be achieved within cell-tolerant limits; enzymatic crosslinking uses biological enzymes such as transglutaminase to complete crosslinking under mild conditions, offering good biocompatibility. A “two-stage crosslinking” strategy is widely adopted: rapid shaping is achieved via physical or ionic crosslinking first, followed by photocrosslinking or enzymatic crosslinking to improve structural stability and functional durability.
III. Key Applications of 3D Bioprinting in Regenerative Medicine
3.1 Tissue Repair and Reconstruction
(1) Bone and Cartilage Tissues
In bone defect repair, 3D bioprinting can customize three-dimensional scaffolds that precisely match a patient’s defect based on imaging data. Internal pore architectures can mimic the porous network of cancellous bone, while osteogenic cells and growth factors such as bone morphogenetic proteins can be incorporated to promote new bone formation and vascular ingrowth. For articular cartilage injury, cartilage-like scaffolds printed from composites of materials such as hyaluronic acid and gelatin with chondrocytes or mesenchymal stem cells may reconstruct a cartilage layer with elasticity and lubrication, and enable gradient reconstruction at the osteochondral interface.
(2) Skin and Soft Tissue Repair
Skin exhibits pronounced layered organization and rich vascular networks. 3D bioprinting can fabricate artificial skin constructs with epidermis–dermis structural features by layered deposition of keratinocytes, fibroblasts, and endothelial cells. In burn treatment and chronic wound repair, such printed skin can provide mechanical protection, promote re-epithelialization and angiogenesis, and reduce the risk of scar formation. For soft tissue defects, elastic materials combined with adipose-derived stem cells can be printed to form soft tissue filling structures with volume maintenance and softness.
3.2 Organ Substitution and Organoid Construction
(1) Functional Organoids
Organoids are small three-dimensional models that recapitulate partial structure and function of human organs. By precisely controlling the spatial distribution of distinct cell populations and microenvironmental parameters, 3D bioprinting can generate multiple tissue-specific organoids, including those of liver, kidney, myocardium, and neural tissues. These organoids can support functions such as drug metabolism, toxicity assessment, and disease modeling, providing experimental platforms closer to human physiology than 2D culture and many animal models for drug screening and mechanistic studies.
(2) Potential for Organ Substitution
Complete replacement of full-sized organs remains at the preclinical stage, with key challenges concentrated on building three-dimensional vascular networks and achieving long-term functional stability. With advances in printable microfluidic networks, degradable vascular templates, and endothelialization strategies, constructs incorporating perfusable channels and branching vascular networks are gradually becoming feasible, laying the technological foundation for on-demand printing of large organs such as the heart and liver. At present, transplantation applications of partially vascularized tissue patches and small organoids are being explored as transitional support for patients with end-stage organ failure.
3.3 Disease Models and Drug Development
(1) In Vitro Disease Models
3D bioprinted organoids and tissue models for tumors, fibrosis, or neurodegenerative diseases can more realistically capture extracellular matrix properties, cell–cell interactions, and drug penetration characteristics. In oncology in particular, printed tumor organoids can incorporate microenvironments composed of tumor cells, stromal cells, and immune cells, improving evaluation of combination regimens involving chemotherapeutics, targeted agents, and immunotherapies.
(2) Drug Screening and Toxicity Evaluation
Personalized organoids derived from patient cells or induced pluripotent stem cells can be used to evaluate efficacy and toxicity across drug candidates or dosing combinations, providing references for individualized clinical dosing strategies. Compared with conventional animal models, 3D bioprinted organoids offer advantages in species relevance, throughput, and reproducibility, helping improve R&D efficiency and reduce development risk.
IV. Engineering and Biological Challenges
4.1 Vascularization and Viability of Large-Volume Tissues
For constructs with clinically relevant thickness, diffusion alone cannot meet cellular demands for oxygen and nutrients, often leading to central necrosis. Therefore, synchronously constructing perfusable microvascular networks during printing, or inducing rapid formation of functional vasculature via endothelial cells post-printing, remains a key bottleneck limiting the generation and function of large-volume tissues and organs.
4.2 Bioink Development and Fine Microenvironmental Control
Bioinks must simultaneously satisfy printability, structural stability, and cell-friendliness during long-term culture. Different tissues have markedly different requirements for stiffness, degradation rate, and bioactive components, and single-material systems often fail to meet multidimensional demands. Achieving fine control of cell fate and tissue remodeling through multicomponent composites, programmable degradation, and spatial gradient design is a major direction in bioink development.
4.3 Quality Control and Clinical Translation
3D bioprinted constructs typically involve variability from both cellular and material sources, making batch-to-batch consistency and long-term stability control more complex than for traditional medical devices. Establishing a quality evaluation framework for bioprinted tissues—including structural accuracy, mechanical performance, cell viability, functional readouts, and safety testing—and developing standardized manufacturing workflows and regulatory frameworks on this basis are essential for clinical translation.
V. Future Development Trends
5.1 4D Bioprinting and Dynamic Tissue Remodeling
4D bioprinting introduces a time dimension on top of three-dimensional fabrication by incorporating smart materials responsive to temperature, pH, enzymes, or specific physiological signals, enabling printed tissues to undergo controllable deformation, degradation, or structural reorganization under in vivo or in vitro stimuli. This dynamic responsiveness more closely resembles native tissue behavior during development and repair, and may be used to build complex folding structures, deployable implants, and adaptive tissue scaffolds.
5.2 Synergistic Applications of Artificial Intelligence and Gene Editing
Artificial intelligence can assist bioprinting and regenerative medicine in multiple ways, such as learning from large experimental datasets to optimize bioink formulations and printing parameters, and predicting how specific structural designs influence cellular behavior and tissue function. Gene-editing technologies can be used to engineer cells to improve anti-apoptotic capacity, enhance differentiation potential, or reduce immunogenicity. Their combination may enable a closed-loop “design–print–evaluate–iterate” optimization paradigm, accelerating the evolution of strategies for constructing functional tissues and organs.
5.3 Interdisciplinary Integration and Standardization Framework Development
Progress in 3D bioprinting and regenerative medicine requires deep integration across life sciences, materials science, mechanical and control engineering, information science, and clinical medicine. As equipment standardization, bioink specification, and evaluation systems improve, clearer technical and regulatory pathways are expected to emerge for indication-oriented tissue repair products, organoid-based drug-screening platforms, and medium-to-long-term organ substitution solutions, thereby laying the foundation for large-scale application and industrialization.
VI. Aladdin-Related Products
Catalog No. | Product Name | Grade and Purity | Applications |
Weak Temperature sensitive Gelatin Methacryloyl | Substitution rate 85-100% | Low-temperature operable cell encapsulation and 3D bioprinting; visible-light/UV photocrosslinked hydrogel fabrication; tissue engineering scaffolds and cell culture matrices. | |
Blue Fluorescent Gelatin Methacryloyl | Double bond modification degree: 30 ± 5% | Fluorescent tracing and imaging of hydrogel networks; morphology/diffusion monitoring in low-crosslink-density GelMA systems; blending with unlabeled GelMA to achieve controllable labeling ratios. | |
Blue Fluorescent Gelatin Methacryloyl | sterile, Double bond modification degree: 60±5% | Fluorescent tracing of sterile cell-encapsulating hydrogels; structural characterization and degradation/migration observation in medium-crosslink-strength GelMA models; imaging of 3D culture and printed constructs. | |
Blue Fluorescent Gelatin Methacryloyl | sterile, Double bond modification degree: 90±5% | Fluorescent tracing of sterile highly crosslinked GelMA hydrogels; imaging and stability assessment of mechanically reinforced GelMA systems; evaluation of scaffold structural uniformity. | |
Chitosan Methacryloyl | sterile, Degree of substitution：35-45%；2%（w/v） | Preparation of sterile injectable/photocrosslinkable chitosan hydrogels; cell/drug delivery and wound-repair hydrogel research; co-network construction with GelMA/AlgMA and related systems. | |
Dextran Methacryloyl(DexMA) | Substitution degree: 5-15%; Storage modulus: ≥200 Pa. | Low-modulus hydrogels for soft-tissue microenvironment mimicry; cell culture and organoid/spheroid support matrices; photocrosslinkable DexMA networks and mechanical tuning via blending. | |
Dextran Methacryloyl (DexMA) | Substitution degree: 5-15%; Storage modulus: ≥500 Pa | Medium-to-higher modulus DexMA hydrogel construction; studies of cellular mechanotransduction and 3D culture scaffolds; blending with GelMA/PEG systems for reinforcement and parameter tuning. | |
Poly-L-lysine-Methacryloyl (PLMA) | Substitution degree 20-30% | Positively charged adhesion-promoting component for hydrogels/surface modification; enhanced cell adhesion/immobilization (compatible with PEG, HA, Alg, etc.); photocrosslinkable films/coatings or co-network formation. | |
Gelatin Methacryloyl Crosslinked Microsphere (MS-C-GM) | Diameter：50-100μm | Cell microcarriers/support particles for 3D culture; granular/composite hydrogel construction; drug/factor loading and sustained-release studies. | |
Gelatin Methacryloyl Crosslinked Microsphere (MS-C-GM) | sterile, Diameter: 50-100μm | Sterile cell microcarriers and 3D culture systems; sterile particle-reinforced hydrogels and injectable filling materials; “granular ink” bioprinting or support-bath system research. | |
Acrylamide polyethylene glycol NHS ester (AC-PEG-NHS) | ACDegree of substitution ≥85%，NHSDegree of substitution≥85% | PEGylation via coupling to amino-containing molecules (proteins/peptides/aminated polysaccharides); fabrication of photocrosslinkable PEG networks or grafting bioactive moieties onto hydrogels; surface/scaffold functionalization. | |
Red Alkene Coupling Hydrogel Fluorescent Dye (DYE-UF-ENE-R) |
| Red fluorescent labeling of hydrogels via ene-click/free-radical reactions; imaging/tracing, mixing uniformity assessment, and diffusion/degradation monitoring; covalent labeling with thiol/ene systems. | |
Green Alkene Coupling Hydrogel Fluorescent Dyes (DYE-UF-ENE-G) |
| Green fluorescent covalent labeling and imaging of hydrogels; morphology, porosity, and interface observation in printed constructs; green-channel tracing in multicolor labeling experiments. | |
Blue Alkene Coupling Hydrogel Fluorescent Dyes (DYE-UF-ENE-B) |
| Blue fluorescent covalent labeling of hydrogels; tracing of network formation, spatial patterning, and gradient construction; suitable for multicolor imaging and control experiments. | |
Green Fluorescent Alginate |
| Fluorescent tracing of alginate systems (ionic crosslinking/composite hydrogels); observation of gelation, diffusion, and degradation; imaging characterization combined with cell encapsulation/microcapsule systems. | |
Green Fluorescent Alginate |
| Imaging labeling and quality assessment of microspheres/microcapsules; phase-distribution/uniformity observation when blended with other polymers; visualization experiments related to rheology and structure. | |
Green Fluorescent Hyaluronic Acid | sterile | Fluorescent tracing of sterile HA hydrogels/ECM-mimicking systems; observation of cellular uptake, migration, and matrix remodeling; imaging characterization for 3D culture and injectable gels. | |
Green Fluorescent Hyaluronic Acid |
| Green fluorescent labeling of HA-related hydrogels or coatings; distribution observation of HA components in composite hydrogels; monitoring of degradation and release behaviors. | |
Methacrylated Carboxymethyl Cellulose (CMCMA) | Marking rate is 40-50%. Methyl propylene residue ≤100ppm | Photo-crosslinkable cellulose-based hydrogels; bioink thickening and rheological modulation; soft-tissue engineering scaffolds; drug delivery systems and cell encapsulation | |
Gelatin Methacryloyl (GelMA) | Marking rate is 85-95%. Methyl propylene residue ≤100ppm | Cell-friendly photo-crosslinkable hydrogels; 3D cell culture and organoid matrices; bioinks for 3D bioprinting; tissue engineering (skin, vascular, cartilage, etc.) and wound healing research | |
Sodium Methacrylate Hyaluronic Acid (HAMA) | Marking rate is 85-95%. Methyl propylene residue ≤100ppm. | ECM-mimicking hydrogels; soft tissue and neural/vascular tissue engineering; cell delivery and microenvironment regulation; formulation with GelMA/AlgMA for bioprinting and mechanical property tuning | |
Sodium Methacrylate Alginate (AlgMA) | Medium viscosity, Marking rate is 10-30%. Methyl propylene residue ≤100ppm | Dual (ionic and photo) crosslinkable hydrogels; cell-encapsulating microspheres/microgels; bioprinting support materials and shape fidelity; drug/protein delivery and controlled release | |
Carboxymethyl Chitosan Methacryloyl (CMCSMA) | Marking rate is 10-20%; Viscosity≤100; Methyl propylene residue ≤100ppm | Photo-crosslinkable chitosan-derivative hydrogels; wound dressings and hemostatic/antibacterial research; adhesive hydrogels and tissue sealing; drug delivery and cell carriers | |
Methylpropenylated chitosan (ChMA) | Viscosity100-300 mpa.s; Marking rate is 10-20%; Methyl propylene residue ≤100ppm | Photo-curable chitosan-based hydrogels; mucosal/tissue adhesive materials; antibacterial and hemostatic wound repair research; composite bioinks (enhanced strength and adhesion) | |
Methacrylated Chondroitin Sulfate (CSMA) | Marking rate is 30-50%; Methyl propylene residue ≤100ppm | Cartilage and osteochondral interface tissue engineering; GAG-mimicking ECM hydrogels; maintenance of cell phenotype and induced differentiation studies; formulation with GelMA/HAMA for bioprinting and enhanced bioactivity | |
Methacrylated Gellan Gum (GGMA) | Gel strength ≥800 g/cm2; Marking rate is 40-60%; Methyl propylene residue ≤100ppm | High-strength photo-crosslinkable hydrogels; injectable/printable scaffold materials; soft tissue engineering and load-bearing hydrogels; bioprinting support, shape retention, and rheological control | |
Acrylated Poloxamer (F127DA) | Marking rate is ＞95%; Methyl propylene residue ≤100ppm | Thermoresponsive and photo-crosslinkable tunable hydrogels; sacrificial templates/sacrificial inks (microchannel and vascularized structure fabrication); drug delivery and sustained release; support or removable materials in bioprinting | |
RGDfK Peptide Acryloyl (RGDfk-AA) | ≥95%(SEC-HPLC) | Introducing RGD cell-adhesion motifs into hydrogels/scaffolds (via coupling or copolymerization with amino/thiol/ene systems); enhancing cell adhesion, spreading, and migration; suitable for 3D culture, tissue engineering, and bioprinting formulation functionalization. |
As an important technological pillar of regenerative medicine, 3D bioprinting is advancing from the stage of structural fabrication toward functional reconstruction and clinical translation. By continuously optimizing bioink systems, printing processes, and vascularization strategies, and by establishing reproducible engineering workflows under robust quality control and regulatory frameworks, it is expected to provide feasible solutions for tissue repair, disease modeling, and organ substitution, offering new therapeutic options to alleviate organ shortages and address complex tissue injuries.
Aladdin: https://www.aladdinsci.com/